The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) in patients (pts) with advanced, EGFR wild-type (wt) Non-Small Cell Lung Cancer (NSCLC): A randomized phase II trial.
 
Tianhong Li
Speakers' Bureau - Pfizer
Research Funding - Astellas Pharma (Inst); Lilly (Inst); Novartis (Inst)
 
Bilal Piperdi
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
William Vincent Walsh
No Relationships to Disclose
 
Mimi Kim
No Relationships to Disclose
 
Laurel A. Beckett
No Relationships to Disclose
 
Huiyu Wen
No Relationships to Disclose
 
Kaili Zhou
No Relationships to Disclose
 
Rasim A. Gucalp
Consulting or Advisory Role - Amgen
Travel, Accommodations, Expenses - Amgen
 
Missak Haigentz
Stock and Other Ownership Interests - Roche
 
Venu Gopal Bathini
No Relationships to Disclose
 
Srikanth Gajavelli
No Relationships to Disclose
 
Meera Sreedhara
No Relationships to Disclose
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Astex Pharmaceuticals; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; Pfizer; Sanofi; Teva; US Diagnostic Services
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst)
 
David R. Gandara
Honoraria - Array BioPharma; AstraZeneca; Celgene; Lilly; Novartis; Synta
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); ImClone Systems (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biomarin; Boehringer Ingelheim; Dava Oncology; Pfizer
 
Roman Perez-Soler
Honoraria - AstraZeneca; Clovis Oncology; Lilly; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Lilly; Roche Pharma AG
Speakers' Bureau - Boehringer Ingelheim; Genentech; Lilly